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Outline
- Introduction: Designer cells for influenza vaccine production
- Results:
 CAP cells in serum free medium (SFM)
 CAP cells in chemically defined medium (CDM)
Low Cell Density
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 CAP cells in CDM
 AGE1.CR cells in CDM
High Cell Density
- Summary 
Host cell lines for influenza
cell line origin tissue immortalization “issues” used by
MDCK dog kidney spontaneous transformation only low passage # Medimmune
Novartis
MDBK bovine kidney spontaneous transformation only low passage # IDT Biologika
Vero monkey kidney spontaneous transformation only low passage #
multilayer
Baxter
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ethical concerns? NRC Canada
(A. Kamen; P17)





duck retinoblasts transformation with 
adenovirus functions
relatively new Ceva Santé 
Animale
EB66 duck embryonic 
stem cells





Cell culture-based influenza production … 
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perfusion/fed batch MDCK: 1 x 107 cells/mL (Bock A. et al. Biotechnol Prog. 2011, 27(1):241-50.) 
perfusion HEK.293: 1 x 107 cells/mL (Petiot  E. et al. BMC Biotechnology 2011, 11:84.)
> 1 x 107 cells/mL
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med. exchange





(log10 HA units/100 µL)
cell spec. productivity 
(virions/cell)
A/PR/8-RKIcapa without med. exch. 4.5 2.3 889
A/PR/8-RKIcapa with med. exch. 5.0 3.2 6400
A/PR/8-RKIcapa with 1:2 dilution 2.3 2.8 5478
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CAP adapted A/PR/8/34 H1N1 influenza in CAP cells grown in PEM medium in 1L biostat STR
CAP
medium PEM
max cell concentration (x 106 cells/mL) 3.0





max HA (log10 HA units/100 µL) 2.5
cell spec. productivity (virions/cell) 2130
→ medium/conditions for virus production needs improvement (slime formation)
CAP in CDM: trypsin & medium exchange
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CAP adapted A/PR/8/34 H1N1 influenza in CAP cells grown in CDM2 medium (Teutocell) in shaker flasks, moi:0.025
virus experimental condition
max cell concentration 
(x 106 cells/mL)
max HA 
(log10 HA units/100 µL)
cell spec. productivity 
(virions/cell)
A/PR/8-RKIcapa without med. exch. 6.1 2.6 1210
A/PR/8-RKIcapa with med. exch. 6.0 2.9 2720
A/PR/8-RKIcapa with 1:2 dilution 6.6 2.9 2290
CAP in CDM: moi
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CAP adapted A/PR/8/34 H1N1 influenza in CAP cells grown in CDM2 medium in shaker flasks
virus experimental condition
max cell concentration 
(x 106 cells/mL)
max HA 
(log10 HA units/100 µL)
cell spec. productivity 
(virions/cell)
A/PR/8-RKIcapa without med. exch. 5.7 2.1 463
A/PR/8-RKIcapa with med. exch. 5.0 2.9 3140
A/PR/8-RKIcapa with 1:2 dilution 6.4 2.8 2100
1E-06 trypsin U/cells
CAP in CDM: 1L batch mode
5.27 x 106 cells/mL
viability
diameter
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(B52)
virus experimental condition
max cell concentration 
(x 106 cells/mL)
max HA 
(log10 HA units/100 µL)
cell spec. productivity 
(virions/cell)
A/PR/8-RKIcapa with 1:2 dilution 5.3 3.0 3880
A/PR/8-RKIcapa without med. exch. 4.0 2.0 537
HA
dead cells
1:2 dilution at toi
ATF for influenza virus production
hemagglutinin
matrix protein: 




(s/s (-) sense RNA;
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ALTERNATING TANGENTIAL FLOW TECHNOLOGY
ATF for influenza virus production
AGE1.CR cells in CDM
batch
5 x 106 + inf.
CAP cells in CDM
batch
5 x 106 + inf.










26 x 106 + inf.
ATF 0.5 µm
22 x 106 + inf.
ATF 0.2 µm










1.75 h perfusion stopped for virus entry
adapted A/PR/8 (RKI) virus seed, 
trypsin: 1 x 10-6 U/cells
start: 1 x 106 cells/mL
perfusion rate manually adjusted according to metabolite conc.
CAP at high cell densities (0.2 µm cut-off)...
24 x 106 cells/mL, no virus (B53) 27 x 106 cells/mL (B58)
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92% viability
91% viability
→ perfusion works up to 27 x 106 cells/mL
→ antifoam helps against slime formation
→ no virus in harvest
Yields for CAP 
batch (B52) ATF (B53) ATF (B58)
HF cut-off 0.2 µm 0.2 µm
passage nr 36 38 47
doubling time (d) 32.4 35.7 36.5
moi 0.025 0.025
seed virus A/PR/8/34 A/PR/8/34
max. perfusion rate (mL/min) 1.3 1.4
total virus harvest (HA) (virions) 2.05E+13 9.89E+13
virus conc (HA) (virions/mL) 2.05E+10 1.10E+11
max HA (log HAU/100µL) 3.00 3.74
max TCID50 (virions/mL) 1.00E+09
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max. cell conc. (cells/mL) 5.27E+06 2.42E+07 2.69E+07
total viable cell numbers (cells) 5.27E+09 2.18E+10 2.42E+10
vol for cell growth (L) 1.0 6.7 5.9
time for cell growth (d) 4.0 10.7 7.0
time to harvest (d) 4.2 9.2
total vol. (L) 1.5 6.7 9.1
space-time-yield (virions/(d x L)) 3.25E+12 1.18E+12
cell specific virus yield (virions/cell) 3883 4086
virus in harvest? no
comment 1:2 dil., no pH control (V) "slime" antifoam
→ perfusion rate is not optimized: space-time-yields can be improved
→ cell specific virus yield is stable: no high cell density effect
AGE1.CR at high cell densities: 0.2 µm cut-off
53 x 106 cells/mL, no virus (B47)
viable cells
48 x 106 cells/mL (B44)
perfusion rate
28 x 106 cells/mL (B51)







→ perfusion works up to 53 x 106 cells/mL with CD-U3 medium
→ virus in harvestsee also Poster 20 
changing cut-off ...
0.2 µm 
28 x 106 cells/mL (B51)
50 kDa




22 x 106 cells/mL (B59)




→ 50 kDa is holding back “virus titer influencing compounds“
→ 0.5 µm: important amount of virus in harvest
HA harvest
Yields for AGE1.CR 
batch (B50) ATF (47) ATF (B44) ATF (B51) ATF (B54) ATF (B59)
HF cut-off 0.2 µm 0.2 µm 0.2 µm 50 kDa 0.5 µm
passage nr 106 35 77 106 52
doubling time (d) 25 34 39 32 44 30
moi 0.025 0.001 0.001 0.001 0.001
seed virus A/PR/8/34 A/PR/8/34 A/PR/8/34 A/PR/8/34 A/PR/8/34
max. perfusion rate (mL/min) 2.6 1.7 1.6 2.9 1.2
total virus harvest (HA) (virions) 7.43E+12 6.12E+13 3.67E+13 1.19E+13 3.46E+13
virus conc (HA) (virions/mL) 7.43E+09 2.19E+10 8.81E+09 1.32E+10 2.18E+10
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→ perfusion rate is not optimized: space-time-yields can be improved
→ cell specific virus yield  is stable: no high cell density effect
max HA (log HAU/100µL) 2.57 3.48 3.38 2.82 3.27
max TCID50 (virions/mL) 3.20E+08 - 4.20E+09 1.00E+10 -
max. cell conc. (cells/mL) 5.75E+06 5.25E+07 4.77E+07 2.81E+07 2.55E+07 2.23E+07
total viable cell numbers (cells) 5.67E+09 4.73E+10 4.77E+10 2.25E+10 2.04E+10 2.01E+10
vol for cell growth (L) 1.0 13.0 5.8 6.4 4.7
time for cell growth (d) 1.90 10.70 10.50 5.60 7.70 6.2
time to harvest (d) 0.79 1.87 1.96 1.06 0.95
total time (d) 2.69 12.37 7.56 8.76 7.15
total vol. (L) 1.5 18.0 8.1 8.1 8.4
space-time-yield (virions/(d x L)) 1.84E+12 2.75E+11 5.96E+11 1.68E+11 5.76E+11
cell specific virus yield (virions/cell) 1310 1283 1631 583 1724
Summary
 CAP cells clearly show a potential for influenza vaccine production
 trypsin activity, virus medium and moi needs to be optimized
 HCD is possible with stable cell specific virus yield for AGE1.CR & CAP
 optimization of perfusion rate & medium can further improve space-time-yield
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 additional options to select HF cut-off for process design















































CAP: adaptation of different viruses
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adaptation (4 passages) of MDCK cell-derived virus seeds to CAP cells
grown in PEM or SFM293 medium in shaker flasks with medium exchange
surface membrane expression of sialyloligosaccharides showed α2,3 and α2,6 sialic acids 
Genzel Y. et al. submitted
N-Glycan patterns for A/PR/8/34 HA
Max Planck Institute Magdeburg Influenza virus production 21September 2011
→ MDCK cells clearly have a different  glycan pattern
other observations
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Cell growth of AGE1.CR in perfusion in CD-U3 medium (PAA) (B51)
- pH increase with ATF start
- slow decrease at 50 kDa?
- metabolite plateau before toi
- strong increase of
metabolites post infection?
- high viability
- smaller than CAP cells
- decrease of cell
concentration during
virus replication
AGE1.CR in batch mode
5.75 x 106 cells/mL
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max. HA titer (log HA10 units/100µL)
virus MDCKadh Vero MDCK.SUS2 AGE1.CR AGE1.CR.pIX HEK293 CAP
A/PR/8/34 H1N1 (RKI) 3.3 2.6 3.0 3.0 2.7 3.0 2.6
A/PR/8/34 H1N1 (NIBSC) 2.6 3.0 n.d. 2.1 2.1 n.d. n.d.
A/Wisconsin/67/2005 H3N2-like HGR (NIBSC) 3.0 2.6 n.d. 2.5 2.4 n.d. n.d.
A/Brisbane/59/2007 H1N1-like HGR (NIBSC) 3.0 n.d. n.d. 2.6 2.3 n.d. 2.4
A/Uruguay/716/2007 H3N2-like HGR (NIBSC) 2.9 1.4 n.d. - - n.d. 2.3
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small scale cultivation: CR in AEM + gln in T-flasks, typical data for: MDCK & Vero in GMEM, MDCK.SUS2 in SMIF8, CAP in 293SFMII
A/WSN/33 H1N1 (Freiburg) 3.3 - n.d. 1.6 - n.d. n.d.
B/Malaysia/2506/2004 (NIBSC) 3.0 - 2.8 2.6 2.9 n.d. n.d.
B/Florida/4/2006 (NIBSC) 2.8 - n.d. n.d. n.d. n.d. 2.5
delNS1 (A/PR/8/34) (Avir Greenhills Biotech.) 1.9 n.d. n.d. 2.3 1.2 n.d. n.d.
B/Lee/40 (ATCC) n.d. n.d. n.d. n.d. n.d. 3.0 n.d.
Equine A/Newmarket/1/93 H3N8 2.8 n.d. n.d. 2.0 1.6 n.d. 1.8
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Le Ru A. et al. Vaccine. 2010; 28(21):3661-71.  Petiot E. et al. BMC Biotechnology 2011, 11:84.
HEK293-SF3F6 cells in 3L STR (Chemap, 85 rpm, HyClone SFM4 Transfx-293, acoustic filter), infl. A/PR/8/34 (moi: 0.001)
perfusion batch batch
cell concentration at toi (x 106 cells/mL) 6.0 6.0 4.0
max. cell concentration (x 106 cells/mL) 10.1 5.8 4.4
max HA (log10 HA units/100 µL) 3.3 2.7 3.0
max. productivity of HA (log HA units/mL * mL harvest) 6.8 6.2 6.5
cell spec. productivity (virions/cell) 3951 1740 4683
Cultivation time, h




peak viability for all > 80%
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Cell growth of AGE1.CR.pIX in batch against HEK293 cells grown in perfusion 3L STR
→ perfusion of AGE1.CR could lead to higher cell densities ??
Le Ru A. et al. Vaccine. 2010; 28(21):3661-71.  Petiot E. et al. BMC Biotechnology. 2011, 11:84.




 Non tumor origin
 Robust and scaleable
 Informed Consent




 Non-oncogenic in humans




 Stable protein expression
 Stable and fast growth
 Suspension
Master Cell Bank
 Fully certified
 Complete documentation
